211 related articles for article (PubMed ID: 16525900)
21. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
[TBL] [Abstract][Full Text] [Related]
22. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
23. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.
Yamashita H; Mori K; Nagao M; Okamoto Y; Morinobu S; Yamawaki S
J Clin Psychiatry; 2004 Nov; 65(11):1525-30. PubMed ID: 15554767
[TBL] [Abstract][Full Text] [Related]
24. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.
Harvey PD; Patterson TL; Potter LS; Zhong K; Brecher M
Am J Psychiatry; 2006 Nov; 163(11):1918-25. PubMed ID: 17074943
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
[TBL] [Abstract][Full Text] [Related]
26. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
[TBL] [Abstract][Full Text] [Related]
28. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
Arango C; Giráldez M; Merchán-Naranjo J; Baeza I; Castro-Fornieles J; Alda JA; Martínez-Cantarero C; Moreno C; de Andrés P; Cuerda C; de la Serna E; Correll CU; Fraguas D; Parellada M
J Am Acad Child Adolesc Psychiatry; 2014 Nov; 53(11):1179-90,1190.e1-4. PubMed ID: 25440308
[TBL] [Abstract][Full Text] [Related]
29. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
[TBL] [Abstract][Full Text] [Related]
30. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
[TBL] [Abstract][Full Text] [Related]
31. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
Jensen JB; Kumra S; Leitten W; Oberstar J; Anjum A; White T; Wozniak J; Lee SS; Schulz SC
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):317-26. PubMed ID: 18759641
[TBL] [Abstract][Full Text] [Related]
32. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
[TBL] [Abstract][Full Text] [Related]
33. [Effect of antipsychotic drugs on life quality of schizophrenic patients: one year follow-up study].
Fang M; Li L; Zhao J; Chen H; Ye M; Guo X; Lu Z; Sun X; Wang C; Xie S; Hu B; Guo T; Ma C; Wang B; Lü L; Liu N; Deng H; Chen Q; Shang X; Gong F; Zhang X; He X; Zhou J; Zhang Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 34(9):850-5. PubMed ID: 19779255
[TBL] [Abstract][Full Text] [Related]
34. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
[TBL] [Abstract][Full Text] [Related]
35. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.
Gurpegui M; Alvarez E; Bousoño M; Ciudad A; Carlos Gómez J; Olivares JM
Eur Neuropsychopharmacol; 2007 Nov; 17(11):725-34. PubMed ID: 17543505
[TBL] [Abstract][Full Text] [Related]
36. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
[TBL] [Abstract][Full Text] [Related]
37. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.
McGrath BM; Tempier RP
Pharmacopsychiatry; 2005 Jul; 38(4):147-57. PubMed ID: 16025416
[TBL] [Abstract][Full Text] [Related]
38. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.
Savina I; Beninger RJ
Schizophr Res; 2007 Aug; 94(1-3):128-38. PubMed ID: 17560766
[TBL] [Abstract][Full Text] [Related]
39. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
Novick D; Ascher-Svanum H; Brugnoli R; Bertsch J; Hong J; Haro JM
J Nerv Ment Dis; 2012 Jul; 200(7):637-43. PubMed ID: 22759944
[TBL] [Abstract][Full Text] [Related]
40. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
